ZA200406491B - Thiazole and oxazole derivativec that modulate ppar activity - Google Patents

Thiazole and oxazole derivativec that modulate ppar activity Download PDF

Info

Publication number: ZA200406491B
Authority: ZA; South Africa
Prior art keywords: methyl; alkyl; thiazol; trifluoromethyl; phenyl
Prior art date: 2002-03-07

Application number

ZA200406491A

Other languages

English (en)

Inventor

Xue-Min Cheng

Noe O Erasga

Gary F Filzen

Andrew G Geyer

Chitase Lee

Bharat K Trivedi

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-07

Filing date

2004-08-16

Publication date

2006-05-31

2004-08-16 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-05-31 Publication of ZA200406491B publication Critical patent/ZA200406491B/en

Links

230000000694 effects Effects 0.000 title description 6
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title description 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
101150014691 PPARA gene Proteins 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims description 59
229910052739 hydrogen Inorganic materials 0.000 claims description 41
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 34
239000001257 hydrogen Substances 0.000 claims description 32
-1 1,3-thiazol-5- yl Chemical group 0.000 claims description 30
150000001875 compounds Chemical class 0.000 claims description 30
125000005842 heteroatom Chemical group 0.000 claims description 30
125000000304 alkynyl group Chemical group 0.000 claims description 26
125000003118 aryl group Chemical group 0.000 claims description 26
125000003342 alkenyl group Chemical group 0.000 claims description 23
229910052760 oxygen Inorganic materials 0.000 claims description 21
229910052799 carbon Inorganic materials 0.000 claims description 19
125000004432 carbon atom Chemical group C* 0.000 claims description 18
229910052717 sulfur Inorganic materials 0.000 claims description 18
238000000034 method Methods 0.000 claims description 15
125000003545 alkoxy group Chemical group 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 13
150000002367 halogens Chemical class 0.000 claims description 12
125000004093 cyano group Chemical group *C#N 0.000 claims description 10
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
125000004429 atom Chemical group 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 7
125000000753 cycloalkyl group Chemical group 0.000 claims description 7
125000001072 heteroaryl group Chemical group 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
125000001188 haloalkyl group Chemical group 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
201000001320 Atherosclerosis Diseases 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
125000005309 thioalkoxy group Chemical group 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
238000004519 manufacturing process Methods 0.000 claims 5
125000002993 cycloalkylene group Chemical group 0.000 claims 4
125000006588 heterocycloalkylene group Chemical group 0.000 claims 4
UDXXBKINFPIINH-UHFFFAOYSA-N 2-[1-methyl-7-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]indol-4-yl]oxyacetic acid Chemical compound S1C(CSC=2C=3N(C)C=CC=3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 UDXXBKINFPIINH-UHFFFAOYSA-N 0.000 claims 1
CMFFIAXBHAHWTO-UHFFFAOYSA-N 2-[4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]naphthalen-1-yl]oxyacetic acid Chemical compound S1C(CSC=2C3=CC=CC=C3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 CMFFIAXBHAHWTO-UHFFFAOYSA-N 0.000 claims 1
FFNOQSNSGSVLIM-UHFFFAOYSA-N 2-[8-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]isoquinolin-5-yl]oxyacetic acid Chemical compound S1C(CSC=2C3=CN=CC=C3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 FFNOQSNSGSVLIM-UHFFFAOYSA-N 0.000 claims 1
FNUBUHFHPGYKBM-UHFFFAOYSA-N 2-[8-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]quinolin-5-yl]oxyacetic acid Chemical compound S1C(CSC=2C3=NC=CC=C3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 FNUBUHFHPGYKBM-UHFFFAOYSA-N 0.000 claims 1
JDHANXYAJKTIPS-UHFFFAOYSA-N 2-[[3-methyl-7-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-1,2-dihydrobenzimidazol-4-yl]oxy]acetic acid Chemical compound CN1CNC2=C1C(OCC(O)=O)=CC=C2SCC(=C(N=1)C)SC=1C1=CC=C(C(F)(F)F)C=C1 JDHANXYAJKTIPS-UHFFFAOYSA-N 0.000 claims 1
PZVRIOMYOFAXMS-UHFFFAOYSA-N 2-[[4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetic acid Chemical compound S1C(CSC=2C=3CCCCC=3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 PZVRIOMYOFAXMS-UHFFFAOYSA-N 0.000 claims 1
NHUXLNSTOFJGPA-UHFFFAOYSA-N 2-[[5-methyl-7-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2,3-dihydro-1-benzofuran-4-yl]oxy]acetic acid Chemical compound S1C(CSC=2C=3OCCC=3C(OCC(O)=O)=C(C)C=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 NHUXLNSTOFJGPA-UHFFFAOYSA-N 0.000 claims 1
WSXPAZMHQPPIOW-UHFFFAOYSA-N 2-[[5-methyl-7-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2,3-dihydro-1h-inden-4-yl]oxy]acetic acid Chemical compound S1C(CSC=2C=3CCCC=3C(OCC(O)=O)=C(C)C=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 WSXPAZMHQPPIOW-UHFFFAOYSA-N 0.000 claims 1
YBEBHGQZPGLEEL-UHFFFAOYSA-N 2-[[7-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2,3-dihydro-1h-inden-4-yl]oxy]acetic acid Chemical compound S1C(CSC=2C=3CCCC=3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 YBEBHGQZPGLEEL-UHFFFAOYSA-N 0.000 claims 1
ZVOQTDHGIWIEBK-UHFFFAOYSA-N 2-[[8-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-4-oxo-2,3-dihydrochromen-5-yl]oxy]acetic acid Chemical compound S1C(CSC=2C=3OCCC(=O)C=3C(OCC(O)=O)=CC=2)=C(C)N=C1C1=CC=C(C(F)(F)F)C=C1 ZVOQTDHGIWIEBK-UHFFFAOYSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
239000004215 Carbon black (E152) Substances 0.000 description 6
150000001721 carbon Chemical group 0.000 description 6
229930195733 hydrocarbon Natural products 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
230000004913 activation Effects 0.000 description 5
125000002947 alkylene group Chemical group 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
208000029078 coronary artery disease Diseases 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010010234 HDL Lipoproteins Proteins 0.000 description 3
102000015779 HDL Lipoproteins Human genes 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
108010007622 LDL Lipoproteins Proteins 0.000 description 3
102000007330 LDL Lipoproteins Human genes 0.000 description 3
208000008589 Obesity Diseases 0.000 description 3
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
108010062497 VLDL Lipoproteins Proteins 0.000 description 3
230000002402 anti-lipaemic effect Effects 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000008103 glucose Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
235000020824 obesity Nutrition 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000003178 anti-diabetic effect Effects 0.000 description 2
229940125708 antidiabetic agent Drugs 0.000 description 2
239000003524 antilipemic agent Substances 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
208000006575 hypertriglyceridemia Diseases 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
125000006039 1-hexenyl group Chemical group 0.000 description 1
125000006023 1-pentenyl group Chemical group 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
125000004825 2,2-dimethylpropylene group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[*:1])C([H])([H])[*:2] 0.000 description 1
150000001473 2,4-thiazolidinediones Chemical class 0.000 description 1
125000006040 2-hexenyl group Chemical group 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
125000006041 3-hexenyl group Chemical group 0.000 description 1
125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101710095342 Apolipoprotein B Proteins 0.000 description 1
102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
229920002911 Colestipol Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
102000007451 Steroid Receptors Human genes 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
229920000080 bile acid sequestrant Polymers 0.000 description 1
229940096699 bile acid sequestrants Drugs 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
229960002604 colestipol Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
150000007978 oxazole derivatives Chemical class 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000003614 peroxisome proliferator Substances 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
125000004962 sulfoxyl group Chemical group 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
102000009310 vitamin D receptors Human genes 0.000 description 1
108050000156 vitamin D receptors Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Steroid Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200406491A 2002-03-07 2004-08-16 Thiazole and oxazole derivativec that modulate ppar activity ZA200406491B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36240002P	2002-03-07	2002-03-07

Publications (1)

Publication Number	Publication Date
ZA200406491B true ZA200406491B (en)	2006-05-31

Family

ID=27789156

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200406491A ZA200406491B (en)	2002-03-07	2004-08-16	Thiazole and oxazole derivativec that modulate ppar activity

Country Status (29)

Country	Link
US (1)	US6833380B2 (fr)
EP (1)	EP1485091A1 (fr)
JP (1)	JP2005524665A (fr)
KR (1)	KR20040091694A (fr)
CN (1)	CN1638768A (fr)
AP (1)	AP2004003123A0 (fr)
AR (1)	AR038883A1 (fr)
AU (1)	AU2003207891A1 (fr)
BR (1)	BR0308221A (fr)
CA (1)	CA2476580A1 (fr)
CO (1)	CO5601013A2 (fr)
EA (1)	EA200401160A1 (fr)
EC (1)	ECSP045275A (fr)
GT (1)	GT200300053A (fr)
HR (1)	HRP20040810A2 (fr)
IL (1)	IL163768A0 (fr)
IS (1)	IS7399A (fr)
MA (1)	MA27182A1 (fr)
MX (1)	MXPA04008624A (fr)
NO (1)	NO20044245L (fr)
OA (1)	OA12781A (fr)
PA (1)	PA8568701A1 (fr)
PE (1)	PE20031010A1 (fr)
PL (1)	PL372971A1 (fr)
TN (1)	TNSN04167A1 (fr)
TW (1)	TW200400027A (fr)
UY (1)	UY27704A1 (fr)
WO (1)	WO2003074052A1 (fr)
ZA (1)	ZA200406491B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6867224B2 (en) *	2002-03-07	2005-03-15	Warner-Lambert Company	Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en)	2002-04-05	2005-04-05	Warner-Lambert Company	Compounds that modulate PPAR activity and methods for their preparation
WO2005060958A1 (fr) *	2003-12-19	2005-07-07	Kalypsys, Inc.	Derives de l'acide (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetique et composes associes en tant que modulateurs du recepteur ppar-delta humain pour le traitement de troubles metaboliques tels que le diabete de type 2
WO2005105736A1 (fr)	2004-05-05	2005-11-10	Novo Nordisk A/S	Nouveaux composes, leur preparation et leur utilisation
ES2352085T3 (es)	2004-05-05	2011-02-15	High Point Pharmaceuticals, Llc	Nuevos compuestos, su preparación y uso.
WO2005115384A2 (fr) *	2004-05-25	2005-12-08	Metabolex, Inc.	Triazoles substitués bicyliques comme modulateurs de ppar et méthodes de préparation
CN1997633A (zh) *	2004-05-25	2007-07-11	麦它波莱克斯股份有限公司	作为ppar调节剂的取代的三唑及其制备方法
ATE529404T1 (de)	2005-06-30	2011-11-15	High Point Pharmaceuticals Llc	Phenoxyessigsäuren als ppar-delta-aktivatoren
CN1896069B (zh) *	2005-07-15	2011-10-05	中国科学院上海药物研究所	一类取代噻唑-4酮化合物、制备方法和用途
BRPI0620468A2 (pt)	2005-12-22	2011-11-08	Transtech Pharma, Inc.	ácidos fenóxi acéticos como ativadores de ppar delta
WO2007101864A2 (fr)	2006-03-09	2007-09-13	High Point Pharmaceuticals, Llc	Nouveaux composés, leur préparation et utilisation
AR059898A1 (es)	2006-03-15	2008-05-07	Janssen Pharmaceutica Nv	Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
PL2200985T3 (pl)	2007-09-14	2011-12-30	Ortho Mcneil Janssen Pharmaceuticals Inc	1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl)	2007-09-14	2011-05-31	Ortho Mcneil Janssen Pharm	1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101801930B (zh)	2007-09-14	2013-01-30	奥梅-杨森制药有限公司	1,3-二取代的-4-苯基-1h-吡啶-2-酮
CN101861316B (zh)	2007-11-14	2013-08-21	奥梅-杨森制药有限公司	咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2344470B1 (fr)	2008-09-02	2013-11-06	Janssen Pharmaceuticals, Inc.	Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate
WO2010043396A1 (fr)	2008-10-16	2010-04-22	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate
JP5690277B2 (ja)	2008-11-28	2015-03-25	ジャンセンファーマシューティカルズ，インコーポレイテッド．	代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
BRPI1010831A2 (pt)	2009-05-12	2016-04-05	Addex Pharmaceuticals Sa	derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh)	2009-05-12	2015-04-29	杨森制药有限公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
US9271967B2 (en)	2010-11-08	2016-03-01	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es)	2010-11-08	2015-05-25	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328203B2 (en)	2010-11-08	2015-03-19	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015035171A1 (fr)	2013-09-09	2015-03-12	High Point Pharmaceuticals, Llc	Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
MX386697B (es)	2014-01-21	2025-03-19	Janssen Pharmaceutica Nv	Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (fr)	2014-01-21	2020-04-20	Janssen Pharmaceutica Nv	Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
CN113045523B (zh) *	2019-12-27	2022-09-23	上海泓博智源医药股份有限公司	一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (fr)	2022-01-25	2023-08-03	Reneo Pharmaceuticals, Inc.	Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997028149A1 (fr)	1996-02-02	1997-08-07	Merck & Co., Inc.	Procede pour augmenter les niveaux de cholesterol hdl
WO1997028137A1 (fr)	1996-02-02	1997-08-07	Merck & Co., Inc.	Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite
CN1233241A (zh)	1996-08-19	1999-10-27	日本烟草产业株式会社	丙酸衍生物及其用途
GB9914977D0 (en)	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
US6417212B1 (en)	1999-08-27	2002-07-09	Eli Lilly & Company	Modulators of peroxisome proliferator activated receptors
JP2004509084A (ja)	2000-08-23	2004-03-25	イーライ・リリー・アンド・カンパニー	オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
CA2418104A1 (fr)	2000-08-23	2002-02-28	Eli Lilly And Company	Derives d'acide oxazolyl-arylpropionique et leur utilisation comme agonistes des ppar
GB0031109D0 (en)	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
GB0031107D0 (en)	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
AU2002233271A1 (en)	2000-12-20	2002-07-01	Glaxo Group Limited	Substitued oxazoles and thiazoles as hppar alpha agonists
GB0111523D0 (en)	2001-05-11	2001-07-04	Glaxo Group Ltd	Chemical compounds
PL367676A1 (en)	2001-05-29	2005-03-07	Kyoto Pharmaceutical Industries, Ltd.	Novel heterocyclic derivatives and medicinal use thereof
HRP20031002A2 (en)	2001-06-07	2004-06-30	Lilly Co Eli	Modulators of peroxisome proliferator activated receptors (ppar)
WO2002102780A1 (fr)	2001-06-18	2002-12-27	Ono Pharmaceutical Co., Ltd.	Compose derive de tetrahydroquinoline et medicament contenant ledit compose comme principe actif
AR036237A1 (es)	2001-07-27	2004-08-25	Bayer Corp	Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
BR0212512A (pt)	2001-09-14	2004-10-26	Tularik Inc	Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
US6867224B2 (en)	2002-03-07	2005-03-15	Warner-Lambert Company	Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en)	2002-03-07	2003-11-06	Xue-Min Cheng	Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en)	2002-04-05	2005-04-05	Warner-Lambert Company	Compounds that modulate PPAR activity and methods for their preparation

2002
- 2002-12-19 US US10/324,278 patent/US6833380B2/en not_active Expired - Fee Related
2003
- 2003-03-03 CA CA002476580A patent/CA2476580A1/fr not_active Abandoned
- 2003-03-03 MX MXPA04008624A patent/MXPA04008624A/es active IP Right Grant
- 2003-03-03 WO PCT/IB2003/000817 patent/WO2003074052A1/fr not_active Ceased
- 2003-03-03 EP EP03704893A patent/EP1485091A1/fr not_active Withdrawn
- 2003-03-03 JP JP2003572569A patent/JP2005524665A/ja not_active Withdrawn
- 2003-03-03 KR KR10-2004-7013962A patent/KR20040091694A/ko not_active Ceased
- 2003-03-03 PL PL03372971A patent/PL372971A1/xx not_active Application Discontinuation
- 2003-03-03 BR BR0308221-0A patent/BR0308221A/pt not_active IP Right Cessation
- 2003-03-03 EA EA200401160A patent/EA200401160A1/ru unknown
- 2003-03-03 IL IL16376803A patent/IL163768A0/xx unknown
- 2003-03-03 OA OA1200400233A patent/OA12781A/en unknown
- 2003-03-03 AP APAP/P/2004/003123A patent/AP2004003123A0/en unknown
- 2003-03-03 AU AU2003207891A patent/AU2003207891A1/en not_active Abandoned
- 2003-03-03 CN CNA038054639A patent/CN1638768A/zh active Pending
- 2003-03-03 HR HRP20040810 patent/HRP20040810A2/hr not_active Application Discontinuation
- 2003-03-05 AR ARP030100739A patent/AR038883A1/es unknown
- 2003-03-05 PE PE2003000214A patent/PE20031010A1/es not_active Application Discontinuation
- 2003-03-06 TW TW092104847A patent/TW200400027A/zh unknown
- 2003-03-07 GT GT200300053A patent/GT200300053A/es unknown
- 2003-03-07 PA PA20038568701A patent/PA8568701A1/es unknown
- 2003-03-07 UY UY27704A patent/UY27704A1/es not_active Application Discontinuation
2004
- 2004-08-12 IS IS7399A patent/IS7399A/is unknown
- 2004-08-16 ZA ZA200406491A patent/ZA200406491B/en unknown
- 2004-08-24 CO CO04082303A patent/CO5601013A2/es not_active Application Discontinuation
- 2004-08-30 MA MA27840A patent/MA27182A1/fr unknown
- 2004-09-03 TN TNP2004000167A patent/TNSN04167A1/fr unknown
- 2004-09-24 EC EC2004005275A patent/ECSP045275A/es unknown
- 2004-10-06 NO NO20044245A patent/NO20044245L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2005524665A (ja)	2005-08-18
HRP20040810A2 (en)	2004-12-31
TW200400027A (en)	2004-01-01
GT200300053A (es)	2003-10-10
MA27182A1 (fr)	2005-01-03
CA2476580A1 (fr)	2003-09-12
PL372971A1 (en)	2005-08-08
TNSN04167A1 (fr)	2007-03-12
EP1485091A1 (fr)	2004-12-15
BR0308221A (pt)	2005-01-04
IL163768A0 (en)	2005-12-18
ECSP045275A (es)	2004-10-26
WO2003074052A1 (fr)	2003-09-12
AR038883A1 (es)	2005-02-02
PA8568701A1 (es)	2003-11-12
UY27704A1 (es)	2003-10-31
NO20044245L (no)	2004-10-06
CO5601013A2 (es)	2006-01-31
IS7399A (is)	2004-08-12
PE20031010A1 (es)	2003-12-12
KR20040091694A (ko)	2004-10-28
US6833380B2 (en)	2004-12-21
CN1638768A (zh)	2005-07-13
EA200401160A1 (ru)	2005-02-24
US20030207916A1 (en)	2003-11-06
AU2003207891A1 (en)	2003-09-16
AP2004003123A0 (en)	2004-09-30
OA12781A (en)	2006-07-07
MXPA04008624A (es)	2004-12-06

Publication	Publication Date	Title
ZA200406491B (en)	2006-05-31	Thiazole and oxazole derivativec that modulate ppar activity
ZA200406068B (en)	2005-09-06	Thiazole and oxazole derivatives which modulate PPAR activity.
RU2312106C2 (ru)	2007-12-10	Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
ZA200100983B (en)	2002-03-05	Substituted oxazoles and thiazoles derivatives as hPPAR gamma and hPPAR alpha activators.
KR101179087B1 (ko)	2012-09-07	인간 단백질 티로신 포스파타아제 억제제 및 이용 방법
EP1007039B1 (fr)	2004-03-03	Nouveaux analogues heterocycliques de composes de diphenylethylene
JP2003503399A (ja)	2003-01-28	チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用
JP2006500384A5 (fr)	2007-01-18
RU2003134150A (ru)	2005-06-10	Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета
KR20170094556A (ko)	2017-08-18	상승적 조성물
RU2005109163A (ru)	2006-01-20	НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPARα И PPARγ
RU2005114373A (ru)	2006-05-10	Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов)
RU2006138485A (ru)	2008-05-10	1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение
KR20050085222A (ko)	2005-08-29	혈청-글루코스-강하 및 혈청-지질-강하 활성을 갖는α-페닐티오카복실산 및 α-페닐옥시카복실산의 용도
ZA200600899B (en)	2007-04-25	Benzoxazepine compound
KR100682696B1 (ko)	2007-02-15	당뇨병 치료제
CN1863799B (zh)	2010-09-22	治疗糖尿病和脂质紊乱的色原烷羧酸衍生物
US20060160870A1 (en)	2006-07-20	3-phenylpropionic acid derivatives
MXPA04007177A (es)	2004-10-29	Alimentacion para animales baja en fosforo y metodo para hacer la misma.
RU2435763C2 (ru)	2011-12-10	Ингибиторы тирозинфосфатазы белка человека и способы применения
RU2005141516A (ru)	2007-07-20	Производные анилина
ZA200407008B (en)	2006-06-28	Compounds that modulate PPAR activity and methods for their preparation
HK1045121B (en)	2005-01-21	Remedies for diabetes
HK1028348B (en)	2004-09-03	Novel heterocyclic analogs of diphenylethylene compounds
HK1185070A (en)	2014-02-07	Human protein tyrosine phosphatase inhibitors and their use